Log in to search using one of your social media accounts:

 

36% Price Drop With a Generic Oral Chemo: Good Enough? 36% Price Drop With a Generic Oral Chemo: Good Enough?
Capecitabine was one of the first oral chemotherapies to come off patent, and the generic version has been quickly accepted.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Generics do not contain branded capecitabine costs in USA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 1, 2017 Category: Drugs & Pharmacology Source Type: news

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
This research article has led to a Practice Changing Update on DynaMed Plus. It concludes that capecitabine adjuvant therapy may improve survival in women with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 19, 2017 Category: Consumer Health News Source Type: news

Adjuvant Capecitabine for Breast Cancer Can Replace CMF After Epirubicin
Replacing a cyclophosphamide-based regimen with oral capecitabine does not sacrifice efficacy in adjuvant therapy for early breast cancer, and improves quality of life, according to a new study. (Source: CancerNetwork)
Source: CancerNetwork - June 28, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news

Your NEJM Group Today: Diabetic Foot Ulcer Recurrence / Capecitabine & Postsurgical Residual Breast Cancer / Colorado Cardiology Opportunity (FREE)
By the Editors Here's what we chose for you from NEJM Group today:NEJM Clinical Practice Center: Review: Foot ulceration is the most common lower-extremity complication … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 19, 2017 Category: Primary Care Source Type: news

Adjuvant Capecitabine Improves Survival in Residual Invasive Breast Cancer
Patients with HER2-negative breast cancer with residual invasive disease following neoadjuvant chemotherapy benefit from adjuvant treatment with capecitabine. (Source: CancerNetwork)
Source: CancerNetwork - June 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news

New chemotherapy approach offers breast cancer patients a better quality of life
(Cancer Research UK) The chemotherapy drug capecitabine gives patients a better quality of life and is as effective at preventing breast cancer from returning as the alternative regimen called CMF, when given following epirubicin. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 6, 2017 Category: Cancer & Oncology Source Type: news

Neratinib Shrunk Brain Mets in Half of HER2+ Breast Cancer Patients
This video examines results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Rachel A. Freedman, MD, MPH Tags: Conferences/ASCO Breast Cancer HER2-Positive Breast Cancer Videos Breast Cancer Source Type: news

Neratinib Shrank Brain Mets in Half of HER2+ Breast Cancer Patients
This video examines results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Rachel A. Freedman, MD, MPH Tags: Conferences/ASCO Breast Cancer HER2-Positive Breast Cancer News Videos Breast Cancer Source Type: news

Certain Breast CA Patients Benefit From Adjuvant Capecitabine
Capecitabine cut risk of relapse, death by 30 percent over five years, researchers say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 1, 2017 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Radiology, Surgery, Journal, Source Type: news

Drug Xeloda Prolongs Survival for Some Breast Cancer Patients
Title: Drug Xeloda Prolongs Survival for Some Breast Cancer PatientsCategory: Health NewsCreated: 5/31/2017 12:00:00 AMLast Editorial Review: 6/1/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 1, 2017 Category: Cancer & Oncology Source Type: news

Drug Xeloda Prolongs Survival for Some Breast Cancer Patients
It cut risk of relapse, death by 30 percent over 5 years, trial found (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - June 1, 2017 Category: Cancer & Oncology Source Type: news

Drug Xeloda Prolongs Survival for Some Breast Cancer Patients
It cut risk of relapse, death by 30 percent over 5 years, trial found (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 31, 2017 Category: Cancer & Oncology Tags: Oncology, News, Source Type: news

Drug Xeloda Prolongs Survival for Some Breast Cancer Patients
It cut risk of relapse, death by 30 percent over 5 years, trial found Source: HealthDay Related MedlinePlus Pages: Breast Cancer (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 31, 2017 Category: Consumer Health News Source Type: news

Drug Xeloda Prolongs Survival for Some Breast Cancer Patients
WEDNESDAY, May 31, 2017 -- A drug called Xeloda can extend the lives of some women whose breast cancer is not wiped out by standard treatment, a new clinical trial finds. Oncologists said the results are " practice-changing. " " This drug is already... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 31, 2017 Category: General Medicine Source Type: news

ASCO: Capecitabine May Extend Survival in Biliary Tract Cancer
Survival benefit seen in those given capecitabine versus surgery alone (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 20, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, Conference News, Source Type: news

Chemo Drug May Buy Time for Those With Bile Duct Cancer
For patients with the rare disease, survival benefit was seen in those given Xeloda, researchers say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 18, 2017 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Nursing, Oncology, News, Source Type: news

Chemo Drug May Buy Time for Those with Bile Duct Cancer
For patients with the rare disease, survival benefit was seen in those given Xeloda, researchers say Source: HealthDay Related MedlinePlus Pages: Bile Duct Cancer, Cancer Chemotherapy (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 18, 2017 Category: Consumer Health News Source Type: news

Adjuvant Oral Chemo in Biliary Tract Cancer Extended Survival
The addition of adjuvant oral chemotherapy with capecitabine extended the overall survival of patients with biliary cancers by a median of 15 months, according to the results of the BILCAP study. (Source: CancerNetwork)
Source: CancerNetwork - May 18, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Gastrointestinal Cancer Liver, Gallbladder, and Biliary Tract Cancers News Source Type: news

Chemo Drug, Xeloda, May Buy Time for Those With Bile Duct Cancer
THURSDAY, May 18, 2017 -- The chemotherapy drug Xeloda may prolong survival in those struck by a type of digestive system cancer, a new study finds. People with bile duct cancer who received the medication lived for an average of about 17 months... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 18, 2017 Category: General Medicine Source Type: news

Chemo Drug May Buy Time for Those With Bile Duct Cancer
THURSDAY, May 18, 2017 -- The chemotherapy drug Xeloda may prolong survival in those struck by a type of digestive system cancer, a new study finds. People with bile duct cancer who received the medication lived for an average of about 17 months... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 18, 2017 Category: General Medicine Source Type: news

Chemo Drug May Buy Time for Those With Bile Duct Cancer
For patients with the rare disease, survival benefit was seen in those given Xeloda, researchers say (Source: Cancercompass News: Colorectal Cancer)
Source: Cancercompass News: Colorectal Cancer - May 18, 2017 Category: Cancer & Oncology Source Type: news

Capecitabine improves post-surgery survival period in bile duct cancer patients
A Cancer Research UK-funded trial (BILCAP) showed that the chemotherapy drug capecitabine increased the survival period of bile duct cancer patients by up to one and a half years after undergoing surgery for the disease. (Source: Drug Development Technology)
Source: Drug Development Technology - May 17, 2017 Category: Pharmaceuticals Source Type: news

Drug improves survival of patients with rare cancer by almost a quarter
(Cancer Research UK) Patients who take capecitabine after surgery for bile duct cancer live for almost a year and a half longer than those not given the drug. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 17, 2017 Category: Cancer & Oncology Source Type: news

Oral chemotherapy extends survival by more than a year in biliary tract cancer
(American Society of Clinical Oncology) A phase III randomized clinical trial of 447 patients with biliary tract cancers (BTCs, cancers of the bile duct and gallbladder) showed that giving capecitabine after surgery extends survival by a median of 15 months compared to surgery alone. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 17, 2017 Category: Cancer & Oncology Source Type: news

ASCO Updates Pancreatic Cancer Guideline to Include Doublet Chemotherapy
ASCO updated a 2016 guideline regarding resected pancreatic cancer to include treatment with adjuvant chemotherapy with gemcitabine and capecitabine. (Source: CancerNetwork)
Source: CancerNetwork - April 24, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gastrointestinal Cancer News Pancreatic Cancer Source Type: news

ASCO Updates Recs on Potentially Curable Pancreatic Cancer
Regimen of gemcitabine, capecitabine preferred in absence of concerns for toxicity, tolerance (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 18, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pathology, Pharmacy, Radiology, Surgery, Journal, Source Type: news

Adding Utidelone Improved Outcomes in Heavily Pretreated Breast Cancer
Combining a genetically engineered epothilone analog known as utidelone with capecitabine significantly improved progression-free survival in women with metastatic breast cancer who were refractory to anthracycline and taxane regimens. (Source: CancerNetwork)
Source: CancerNetwork - February 17, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news

New drug treatment for pancreatic cancer 'extends survival'
Conclusion Pancreatic cancer is one of the toughest cancers to treat, with lower survival rates than many other cancers. Surgery is usually the first treatment, where possible. Some people also have chemotherapy or radiotherapy. Recent studies have looked into how different types of chemotherapy might help improve survival. This study shows that a combination of two chemotherapy drugs may help people live longer than taking one drug alone after surgery. But this doesn't mean everyone taking those drugs will survive at least five years, despite the media headlines. The researchers estimate 28.8%, or just over a quarter...
Source: NHS News Feed - January 25, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

New drugs hope for pancreatic cancer sufferers
Pairing the chemotherapy drugs gemcitabine and capecitabine dramatically increases the chances of people with pancreatic cancer living at least five years, trial results have shown. (Source: the Mail online | Health)
Source: the Mail online | Health - January 25, 2017 Category: Consumer Health News Source Type: news

Study establishes new standard of care for pancreatic cancer patients
(Cancer Research UK) A combination of two chemotherapy drugs -- gemcitabine and capecitabine -- should be the new standard of care for pancreatic cancer patients who have had surgery to remove their tumor. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 24, 2017 Category: Cancer & Oncology Source Type: news

Capecitabine (Xeloda) Tablets (Capecitabine Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 17, 2017 Category: Drugs & Pharmacology Source Type: news

Avoiding over-the-counter heartburn medications could save cancer patients' lives
Something as seemingly harmless as a heartburn pill could lead cancer patients to take a turn for the worse. A new study has discovered that proton pump inhibitors, which are very common medications for heartburn and gastrointestinal bleeding, decrease effects of capecitabine, a type of chemotherapy usually prescribed to gastric cancer patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 16, 2016 Category: Science Source Type: news

Avoiding over-the-counter heartburn meds could save cancer patients' lives
(University of Alberta Faculty of Medicine& Dentistry) Something as seemingly harmless as a heartburn pill could lead cancer patients to take a turn for the worse. A University of Alberta study published in the journal JAMA Oncology discovered that proton pump inhibitors, which are very common medications for heartburn and gastrointestinal bleeding, decrease effects of capecitabine, a type of chemotherapy usually prescribed to gastric cancer patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 15, 2016 Category: Global & Universal Source Type: news

Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer
A 44-year-old patient with a history of stage IIB colorectal cancer at the hepatic flexure, invading the duodenum and pancreas, was initially diagnosed in September 2005 and received modified Whipple surgery and 8 cycles of adjuvant chemotherapy with capecitabine and oxaliplatin every 3 weeks. (Source: CancerNetwork)
Source: CancerNetwork - November 15, 2016 Category: Cancer & Oncology Authors: Henning Schade, MD Lindsey Davis, MD Peter Kabos, MD Tags: Case Studies Colorectal Cancer Oncology Journal Source Type: news

Xeloda (Capecitabine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 19, 2016 Category: Drugs & Pharmacology Source Type: news

Fingerprints Disappear During Capecitabine Therapy Fingerprints Disappear During Capecitabine Therapy
The commonly used chemotherapy agent capecitabine can leave many patients without fingerprints, but the effect is temporary.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 29, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Anti-Cancer Agent "Xeloda®", Obtained Approval for Additional Indication of "Adjuvant Chemotherapy for Rectal Cancer"
(Source: Roche Investor Update)
Source: Roche Investor Update - August 26, 2016 Category: Pharmaceuticals Source Type: news

Chemotherapy Plus Bevacizumab Promising in Advanced TNBC
A triplet regimen including paclitaxel, capecitabine, and bevacizumab showed efficacy and safety in women with advanced triple-negative breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Triple-Negative Breast Cancer Source Type: news

Gemzar-Xeloda Tx: The New Standard in Pancreatic Ca?
(MedPage Today) -- Five-year survival reaches all-time high in post-surgical patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 5, 2016 Category: Hematology Source Type: news

Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer
WILMINGTON, Del.--(Healthcare Sales & Marketing Network)--Incyte Corporation (Nasdaq: INCY) announced today its decision to discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in combination with capecitabine for the second-line treatment of ... Biopharmaceuticals, OncologyIncyte, JANUS 1, ruxolitinib, capecitabine, pancreatic cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 11, 2016 Category: Pharmaceuticals Source Type: news

Metronomic Capecitabine as mCRC Maintenance Therapy Metronomic Capecitabine as mCRC Maintenance Therapy
Dr David Kerr discusses a small study that provides provocative results for using metronomic, low-dose, oral capecitabine as single-agent maintenance therapy in advanced colorectal cancer. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 25, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Is Capecitabine New Standard in Pre-op Rectal Cancer?Is Capecitabine New Standard in Pre-op Rectal Cancer?
Dr David Kerr reports on a study in which oral capecitabine beat continuous-infusion 5-FU 'fairly and squarely' in tumor control of early rectal cancer, which may prove a new standard of practice. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 15, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

CTCA at Western Regional Medical Center advances combination immunotherapy clinical trial
(Cancer Treatment Centers of America) Cancer Treatment Centers of America® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona, has announced the launch of Phase II of the NivoPlus clinical trial, which combines the immunotherapeutic agent nivolumab with chemotherapy drugs irinotecan and capecitabine. The use of nivolumab is considered investigational in this study. The NivoPlus clinical trial aims to enlist as many as 49 patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 8, 2016 Category: Cancer & Oncology Source Type: news

Antidote for Chemotherapy Overdosing Approved
(MedPage Today) -- Drug blocks cell damage from fluorouracil and capecitabine (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 11, 2015 Category: American Health Source Type: news

FDA approves first emergency treatment for overdose of certain types of chemotherapy
The U.S. Food and Drug Administration today approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments. (Source: Food and Drug Administration)
Source: Food and Drug Administration - December 11, 2015 Category: American Health Source Type: news

Treating Residual Tumor Boosts Breast Cancer Survival (CME/CE)
(MedPage Today) -- Adjuvant capecitabine after incomplete response to neoadjuvant therapy (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - December 11, 2015 Category: OBGYN Source Type: news

A 'Major, Major Finding' in Managing Residual Breast Cancer A 'Major, Major Finding' in Managing Residual Breast Cancer
The addition of capecitabine to standard care for HER2-negative breast cancer patients with residual invasive disease after neoadjuvant chemo and surgery improved disease-free and overall survival. Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 9, 2015 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Breast Cancer Drugs Battle Disease’s Return
Xeloda lowered risk by a third, while Xgeva lowered chances by 18 percent, researchers report (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 9, 2015 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Oncology, Pharmacy, Research, News, Source Type: news

Tykerb –Lapatinib - A Targeted Biologic...
Tykerb (lapatinib) is a targeted biologic therapy given as treatment for HER2 positive metastatic breast cancer. Tykerb can be taken with Xeloda, another oral chemotherapy drug, to extend survival and prevent the progression of advanced breast cancer. Read about how Tykerb works, possible side effects and drug interactions. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - November 29, 2015 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news